New hope for kids with resistant cancers: experimental drug CUDC-907 enters human testing
NCT ID NCT02909777
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This early-stage trial tested a new drug called CUDC-907 in 26 children and young adults (ages 1–21) with solid tumors, brain tumors, or lymphoma that had come back or stopped responding to treatment. The main goal was to find safe doses and understand side effects. Researchers also looked at how long the drug stayed in the body and whether it helped control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Texas Children's, Baylor College of Medicine
Houston, Texas, 77030, United States
-
University of California, San Francisco, Benioff Children's Hospital
San Francisco, California, 94158, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CUDC-907
What this could lead to
If it works, this could point toward a new treatment option for children with cancers that have not responded to standard therapy.
What could go wrong
This is an early Phase 1 trial with only 26 participants, focused on safety and dosing. It is too small to prove effectiveness, and the drug may not work or could have significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.